Company Profile

PreClinOmics Inc (AKA:PCO)
Profile last edited on: 5/3/19      CAGE: 483F9      UEI:

Business Identifier: Drug discovery and development research for metabolic syndrome and polycystic kidney disease
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7918 Zionsville Road
Indianapolis, IN 46268
   (317) 872-6001
Location: Single
Congr. District: 05
County: Marion

Public Profile

In March 2016 it was announced that PreClinOmics had been acquired by CrownBio a wholly owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) CrownBo was itself acquired in Decemebr 2017 by JSR Life Sciences . ClinOmics Inc had been a preclinical contract research company primarily focused in supporting drug discovery and development research in the therapeutic areas of metabolic, renal, and cardiovascular diseases. The firm specializes in the design and execution of client studies in research areas such as metabolic syndrome, obesity, diabetes, cardiovascular, renal (including polycystic kidney disease), and neurology. The firm’s flexible workflow processes enable rapid transition from inquiry to study initiation while their technologies support a broad range of study designs, including QNMR, telemetry, Oxymax, Meso-Scale Discovery, chemiluminescence and rtPCR. The companies in-house breeding programs can also provide animal models for Metabolic Disease, (the ZDSD rat and FATZO mouse) and Polycystic Kidney Disease (PCY and JCK mouse) research

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $1,485,419
Project Title: Obese Diabetic (Type Ii) Mouse Model Without Leptin/Leptin-Receptor Defects
2009 2 NIH $1,197,462
Project Title: Obese diabetic rat model w/o leptin/leptin-receptor defe

Key People / Management

  Richard G Peterson -- President, EVP Research and Development, CSO and co-founder

  Charles V Jackson -- Director, Research

  Joe Pesek -- Co-Founder; Chief Executive Officer